Pharma 4.0 is no longer a future ambition; it’s the baseline. The ability to operate with real-time data, integrated systems, ...

As excitement builds around GLP-1s and their expanding list of potential indications, the conversation is shifting from hype ...

Grant funding calls are often over-subscribed and success rates can be low. Excellent applications sometimes fail to be ...

The UK has started a 'world-first' gonorrhoea vaccination programme that is designed to prevent thousands of cases and save ...

EVERSANA – which is pharmaphorum's parent company – said that The AI Agency has been set up in collaboration with Google and draws on the tech giant's validated, compliant, and powerful AI, including ...

Vertex already has FDA approval for NaV1.8 inhibitor Journavx (suzetrigine) in acute pain, with late-stage trials on the go ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

Across the world, there are reports of shortages of common antibiotics. Ben Hargreaves examines why these shortages are happening and what is being done in the background to return supply to normal.

A trade organisation representing pharma manufacturers in Europe has said plans to restrict the use of fluorinated substances known as PFAS could make manufacturing “grind to a halt” and ...

After decades of turmoil, Iraq’s healthcare sector is growing fast – but the country still holds some unique challenges for companies looking to enter its market. We spoke to Ali Mosawi ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...

Sobi starts rolling application for refractory gout drug SEL-212 in the US, hoping to take on Amgen’s Krystexxa in the market.